Astec LifeSciences Limited has informed the Exchange regarding Board meeting held on July 28, 2025.

Revenue growth above 20%Net loss reportedEBITDA margin expansionDebt to equity above the thresholdResults View source PDF Explain this filing

ASTEC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.1%Reaction day

₹893.50

prior close

₹878.20

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.2%-4.9% vs market

Pesticides & Agrochemicals peers, median of 25sector+0.5%-6.6% vs sector

On the reaction day the stock moved 4.9 pts less than Nifty Microcap 250 and 6.6 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-1.6

15m

-3.6

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.1-1.2-4.9+0.5-6.6

Next day

-2.0+0.3-2.2+3.3-5.3

-3.0+0.6-3.5+4.4-7.3

-0.1-0.1+0.0+3.8-3.9

-1.1-1.7+0.7+1.3-2.3

-1.4-1.2-0.2+0.8-2.2

-5.8-2.6-3.1-0.9-4.9

15d

-7.1-1.0-6.1-5.4-1.7

-3.7-3.9+0.2-7.3+3.5

-9.3-4.2-5.2-10.0+0.6

-23.4-0.7-22.8-12.6-10.9

UpDownMarket · Nifty Microcap 250Sector · Pesticides & Agrochemicals peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Astec LifeSciences' Board approved unaudited Q1 FY26 (quarter ended June 30, 2025) results, with revenue from operations rising to Rs. 9,108 lakhs from Rs. 6,937 lakhs a year ago — a strong ~31% year-on-year growth. Despite the revenue jump, the company stayed in the red with a net loss of Rs. 3,306 lakhs (standalone), though the loss was narrower than Rs. 3,974 lakhs in Q1 FY25. Operating margin improved sharply from -66.7% to -12.1%, signalling cost-side progress but still negative. The auditor (BSR & Co. LLP) issued an unmodified limited review opinion on both standalone and consolidated results. The company's debt-equity ratio climbed to 2.96 (from 1.58 a year ago), with negative DSCR and ISCR, and working capital is negative. The Board noted that the ongoing Rights Issue of up to Rs. 249.35 crore (at Rs. 890/share, 1:7 ratio) closed on the same day.

Likely market impact

The strong revenue growth and narrowing losses are positives, but persistent net losses, a deteriorating debt-equity ratio above 2.9, and negative debt service coverage ratios keep the stock under earnings pressure. The Rs. 249 crore rights issue closing on the same day is a key near-term event that will dilute existing shareholders but strengthen the balance sheet.